Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2017

01-05-2017 | Urologic Oncology

The Differential Impact of Body Mass Index and the Feature of Metabolic Syndrome on Oncological Outcomes Following Different Surgical Procedures in Japanese Men with Prostate Cancer

Authors: Masaki Shiota, MD, PhD, Ario Takeuchi, MD, PhD, Masaaki Sugimoto, MD, PhD, Eiji Kashiwagi, MD, PhD, Takashi Dejima, MD, PhD, Keijiro Kiyoshima, MD, PhD, Junichi Inokuchi, MD, PhD, Katsunori Tatsugami, MD, PhD, Akira Yokomizo, MD, PhD, Masatoshi Eto, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2017

Login to get access

Abstract

Purpose

This study aimed to examine the differential impact of body mass index and the feature of metabolic syndrome (MetS; obesity, hypertension, diabetes mellitus, and dyslipidemia) on biochemical recurrence (BCR) following radical prostatectomy (RP) treatment for prostate cancer using different surgical procedures.

Methods

This study included 283 Japanese patients with clinically localized prostate cancer who were treated with RP between 2008 and 2012. The prognostic significance of overweight and the feature of MetS were analyzed according to surgical procedures.

Results

BCR occurred in 68/283 (24.0%) men. Overweight and the feature of MetS were predictors of BCR in patients who had undergone open RP (ORP), but not in those treated with laparoscopic surgery. Multivariate analyses incorporating preoperative and postoperative risk factors revealed that overweight and the feature of MetS were independent BCR risk factors when treated with ORP.

Conclusions

In Japanese men, overweight and the feature of MetS were associated with worse outcomes following RP, particularly ORP, compared with those following laparoscopic surgery. These results suggest that laparoscopic surgery can overcome the surgical challenges associated with abdominal obesity.
Appendix
Available only for authorised users
Literature
1.
2.
Faria EF, Chapin BF, Muller RL, Machado RD, Reis RB, Matin SF. Radical prostatectomy for locally advanced prostate cancer: current status. Urology. 2015;86(1):10–5.CrossRefPubMed
3.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–7.CrossRefPubMed
4.
Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007;51(5):1175–84.CrossRefPubMed
5.
Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2):517–23.CrossRefPubMed
6.
Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85(1):60–7.CrossRefPubMed
7.
Cleeman JI. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97.CrossRef
8.
Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care. 2011;34(1):216–9.CrossRefPubMed
9.
Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, et al. Prevalence of metabolic syndrome in the general Japanese population in 2000. J Atheroscler Thromb. 2006;13(4):202–8.CrossRefPubMed
10.
Rhee H, Vela I, Chung E. Metabolic syndrome and prostate cancer: a review of complex interplay amongst various endocrine factors in the pathophysiology and progression of prostate cancer. Horm Cancer. 2016;7(2):75–83.CrossRefPubMed
11.
Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomark Prev. 2004;13(10):1646–50.
12.
Castillejos-Molina R, Rodríguez-Covarrubias F, Sotomayor M, Gómez-Alvarado MO, Villalobos-Gollás M, Gabilondo F, et al. Impact of metabolic syndrome on biochemical recurrence of prostate cancer after radical prostatectomy. Urol Int. 2011;87(3):270–5.CrossRefPubMed
13.
Häggström C, Stocks T, Ulmert D, Bjørge T, Ulmer H, Hallmans G, et al. Prospective study on metabolic factors and risk of prostate cancer. Cancer. 2012;118(24):6199–206.CrossRefPubMed
14.
Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, Inokuchi J, et al. The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy. J Surg Oncol. 2014;110(4):476–81.CrossRefPubMed
15.
Post JM, Beebe-Dimmer JL, Morgenstern H, Neslund-Dudas C, Bock CH, Nock N, et al. The metabolic syndrome and biochemical recurrence following radical prostatectomy. Prostate Cancer. 2011;2011:245642.CrossRefPubMedPubMedCentral
16.
Jaggers JR, Sui X, Hooker SP, LaMonte MJ, Matthews CE, Hand GA, et al. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer. 2009;45(10):1831–8.CrossRefPubMedPubMedCentral
17.
Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control. 2009;20(7):1181–92.CrossRefPubMed
18.
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.CrossRefPubMed
19.
Naito S, Kuroiwa K, Kinukawa N, Goto K, Koga H, Ogawa O, et al. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer. J Urol. 2008;180(3):904–9.CrossRefPubMed
20.
Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA, et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol. 2005;174(3):919–22.CrossRefPubMed
21.
Komaru A, Kamiya N, Suzuki H, Endo T, Takano M, Yano M, et al. Implications of body mass index in Japanese patients with prostate cancer who had undergone radical prostatectomy. Jpn J Clin Oncol. 2010;40(4):353–9.CrossRefPubMed
22.
Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res. 2011;4(4):486–501.CrossRef
23.
Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22(3):439–45.CrossRefPubMed
24.
Kheterpal E, Sammon JD, Diaz M, Bhandari A, Trinh QD, Pokala N, et al. Effect of metabolic syndrome on pathologic features of prostate cancer. Urol Oncol. 2013;31(7):1054–9.CrossRefPubMed
25.
Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, et al. Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol. 2005;174(5):1798–801.CrossRefPubMed
26.
Park SW, Readal N, Jeong BC, Humphreys EB, Epstein JI, Partin AW, et al. Risk factors for intraprostatic incision into malignant glands at radical prostatectomy. Eur Urol. 2015;68(2):311–6.CrossRefPubMed
27.
Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004;22(3):446–53.CrossRefPubMed
28.
Freedland SJ, Bañez LL, Sun LL, Fitzsimons NJ, Moul JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis. 2009;12(3):259–63.CrossRefPubMed
29.
Jayachandran J, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, et al. Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int. 2008;102(8):964–8.CrossRefPubMedPubMedCentral
30.
Moskovic DJ, Lavery HJ, Rehman J, Nabizada-Pace F, Brajtbord J, Samadi DB. High body mass index does not affect outcomes following robotic assisted laparoscopic prostatectomy. Can J Urol. 2010;17(4):5291–8.PubMed
31.
Sundi D, Reese AC, Mettee LZ, Trock BJ, Pavlovich CP. Laparoscopic and robotic radical prostatectomy outcomes in obese and extremely obese men. Urology. 2013;82(3):600–5.CrossRefPubMedPubMedCentral
32.
33.
Froehner M, Litz R, Manseck A, Hakenberg OW, Leike S, Albrecht DM, et al. Relationship of comorbidity, age and perioperative complications in patients undergoing radical prostatectomy. Urol Int. 2001;67(4):283–8.CrossRefPubMed
34.
Kamerer A, Basler J, Thompson I. Novel technique of Vest suture vesicourethral anastomosis in morbidly obese patient undergoing radical retropubic prostatectomy. J Urol. 2003;170(1):174.CrossRefPubMed
35.
Berryhill R Jr, Jhaveri J, Yadav R, Leung R, Rao S, El-Hakim A, et al. Robotic prostatectomy: a review of outcomes compared with laparoscopic and open approaches. Urology. 2008;72(1):15–23.CrossRefPubMed
36.
Brown JA, Rodin DM, Lee B, Dahl DM. Laparoscopic radical prostatectomy and body mass index: an assessment of 151 sequential cases. J Urol. 2005;173(2):442–5.CrossRefPubMed
37.
Mikhail AA, Stockton BR, Orvieto MA, Chien GW, Gong EM, Zorn KC, et al. Robotic-assisted laparoscopic prostatectomy in overweight and obese patients. Urology. 2006;67(4):774–9.CrossRefPubMed
38.
Herman MP, Raman JD, Dong S, Samadi D, Scherr DS. Increasing body mass index negatively impacts outcomes following robotic radical prostatectomy. JSLS. 2007;11(4):438–42.PubMedPubMedCentral
39.
Boorjian SA, Crispen PL, Carlson RE, Rangel LJ, Karnes RJ, Frank I, et al. Impact of obesity on clinicopathologic outcomes after robot-assisted laparoscopic prostatectomy. J Endourol. 2008;22(7):1471–6.CrossRefPubMed
40.
Wiltz AL, Shikanov S, Eggener SE, Katz MH, Thong AE, Steinberg GD, et al. Robotic radical prostatectomy in overweight and obese patients: oncological and validated-functional outcomes. Urology. 2009;73(2):316–22.CrossRefPubMed
41.
Zilberman DE, Tsivian M, Yong D, Ferrandino MN, Albala DM. Does body mass index have an impact on the rate and location of positive surgical margins following robot assisted radical prostatectomy? Urol Oncol. 2012;30(6):790–3.CrossRefPubMed
42.
Lloyd JC, Bañez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, et al. Estimated blood loss as a predictor of PSA recurrence after radical prostatectomy: results from the SEARCH database. BJU Int. 2010;105(3):347–51.CrossRefPubMed
43.
Kang M, Jeong CW, Ku JH, Kwak C, Kim HH. Hypertriglyceridemia is a potential preoperative predictor for biochemical recurrence after radical prostatectomy. PLoS ONE. 2015;10(3):e0122438.CrossRefPubMedPubMedCentral
44.
Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013;105(24):1881–90.CrossRefPubMedPubMedCentral
Metadata
Title
The Differential Impact of Body Mass Index and the Feature of Metabolic Syndrome on Oncological Outcomes Following Different Surgical Procedures in Japanese Men with Prostate Cancer
Authors
Masaki Shiota, MD, PhD
Ario Takeuchi, MD, PhD
Masaaki Sugimoto, MD, PhD
Eiji Kashiwagi, MD, PhD
Takashi Dejima, MD, PhD
Keijiro Kiyoshima, MD, PhD
Junichi Inokuchi, MD, PhD
Katsunori Tatsugami, MD, PhD
Akira Yokomizo, MD, PhD
Masatoshi Eto, MD, PhD
Publication date
01-05-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5705-2

Other articles of this Issue 5/2017

Annals of Surgical Oncology 5/2017 Go to the issue

Breast Oncology

Reliability of the Ki67-Labelling Index in Core Needle Biopsies of Luminal Breast Cancers is Unaffected by Biopsy Volume

Gynecologic Oncology

Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis

Gastrointestinal Oncology

Intraperitoneal Administration of Plasma-Activated Medium: Proposal of a Novel Treatment Option for Peritoneal Metastasis From Gastric Cancer

Colorectal Cancer

Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypN0 Rectal Cancer

Colorectal Cancer

An Optimal Approach for Laparoscopic D3 Lymphadenectomy Plus Complete Mesocolic Excision (D3+CME) for Right-Sided Colon Cancer

Gynecologic Oncology

Treatment Preferences for Routine Lymphadenectomy Versus No Lymphadenectomy in Early-Stage Endometrial Cancer